News Release

Nuwellis, Inc. Announces First Quarter 2023 Financial Results

May 9, 2023

MINNEAPOLIS, May 09, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2023.

  • Revenue of $1.8 million for the first quarter 2023, a 5% decrease over the prior-year period.
  • By segment, first quarter 2023 revenue in Heart Failure increased approximately 21% over the same period last year, while Pediatrics and Critical Care declined approximately 28% and 4%, respectively. The decline in Pediatrics was primarily driven by lower patient volume in large hospital accounts.
  • Gross margin of 58.4% in the first quarter 2023 increased 120 basis points from the same period last year.
  • Announced peer-reviewed publication of clinical trials analysis by A. Kazory, et al, advocating earlier and expanded use of ultrafiltration for diuretics-resistant patients suffering from heart failure as well as kidney disease, sepsis, and other indications.
  • Cash, cash equivalents, and marketable securities of $12.1 million and no debt as of March 31, 2023.

“With growth in our heart failure segment fueled by new clinical evidence, and an active pipeline of business development activities, our team is excited to continue executing on our growth agenda, utilizing our growing body of clinical evidence that supports use of the Aquadex ultrafiltration therapy as a mechanical fluid removal solution for fluid-overloaded patients across multiple hospital specialty units. We remain committed to making Aquadex the standard of care for patients with fluid overload who are not responsive to conventional diuretics, and we look forward to increased sales momentum as we continue to build awareness and drive market penetration,” said Nestor Jaramillo, Jr., President & CEO of Nuwellis.

First Quarter 2023 Financial Results

Revenue for the first quarter of 2023 was $1.8 million, compared to $1.9 million in the prior-year period.

Gross margin was 58.4% for the first quarter of 2023, compared to 57.2% in the prior-year period, an increase of 120 basis points, driven primarily by pricing increases that were effective in the second quarter of 2022.

Selling, general and administrative expenses for the first quarter of 2023 were $5.5 million, compared to $4.4 million in the prior-year period. The increase was primarily due to increased professional fees associated with strategic initiatives and increased audit and legal expenses.

First quarter research and development expenses were $1.4 million, compared to $1.1 million in the first quarter of 2022, reflecting increased product development costs related to the ongoing development of the Company’s dedicated pediatric device.

Net loss for the first quarter of 2023 was $6.5 million, or a loss of $5.76 per basic and diluted common share, compared to a net loss of $4.5 million, or a loss of $42.45 per basic and diluted common share, in the prior-year period. The current period loss includes a non-recurring, non-cash expense of approximately $755,000 related to the revaluation of the warrant liability associated with the Company’s October 2022 financing.

At March 31, 2023, the Company had cash, cash equivalents, and marketable securities of approximately $12.1 million and no debt, with approximately 1.2 million common shares outstanding.

Webcast and Conference Call Information
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance.

To access the live webcast, please visit the Investors page of the Nuwellis website at Alternatively, you may access the live conference call by dialing 1-833-816-1404 (U.S) or 1-412-317-0497 (international) and using the conference ID: 10177112. An audio archive of the webcast will be available following the call on the Investors page at

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit or visit us on LinkedIn.

About the Aquadex SmartFlow® System 
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible, and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg. or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies. 

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2023 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Vivian Cervantes
Gilmartin Group

Annika Parish

Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
    March 31,
    December 31,

ASSETS   (unaudited)          
Current assets              
Cash and cash equivalents $ 11,515   $ 17,737    
Marketable securities   575     569    
Accounts receivable   1,301     1,406    
Inventories, net   2,742     2,661    
Other current assets   477     396    
Total current assets   16,610     22,769    
Property, plant and equipment, net   907     980    
Operating lease right-of-use asset   856     903    
Other assets   106     21    
TOTAL ASSETS $ 18,479   $ 24,673    
Current liabilities              
Accounts payable and accrued liabilities $ 2,524   $ 2,245    
Accrued compensation   1,312     2,161    
Current portion of operating lease liability   201     196    
Current portion of finance lease liability   21     28    
Other current liabilities   49     58    
Total current liabilities   4,107     4,688    
Common stock warrant liability       6,868    
Operating lease liability   708     760    
Total liabilities   4,815     12,316    
Commitments and contingencies              
Stockholders’ equity              
Series A junior participating preferred stock as of March 31, 2023 and December 31, 2022, par value $0.0001 per share; authorized 30,000 shares, none outstanding          
Series F convertible preferred stock as of both March 31, 2023 and December 31, 2022, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares          
Series I convertible preferred stock as of March 31, 2023 and December 31, 2022, par value $0.0001; authorized 1,049,280, issued and outstanding none and 1,049,280, respectively
Preferred stock as of both March 31, 2023 and December 31, 2022, par value
$0.0001 per share; authorized 39,969,873 shares, none outstanding
Common stock as of March 31, 2023 and December 31, 2022, par value
$0.0001 per share; authorized 100,000,000 shares, issued and outstanding 1,206,932 and 536,394 shares, respectively
Additional paid-in capital   287,529     279,736    
Accumulated other comprehensive income:              
Foreign currency translation adjustment   (25 )   (18 )  
Unrealized gain on marketable securities   62     56    
Accumulated deficit   (273,902 )   (267,417 )  
Total stockholders’ equity   13,664     12,357    

Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
    Three months ended
March 31,
    2023     2022    
Net sales $ 1,826   $ 1,926    
Cost of goods sold   759     824    
Gross profit   1,067     1,102    
Operating expenses:              
Selling, general and administrative   5,490     4,412    
Research and development   1,428     1,106    
Total operating expenses   6,918     5,518    
Loss from operations   (5,851 )   (4,416 )  
Other income (expense), net   123     (55 )  
Change in fair value of warrant liability   (755 )      
Loss before income taxes   (6,483 )   (4,471 )  
Income tax expense   (2 )   (2 )  
Net loss $ (6,485 ) $ (4,473 )  
Basic and diluted loss per share $ (5.76 ) $ (42.45 )  
Weighted average shares outstanding – basic and diluted   1,126     105    
Other comprehensive loss:              
Unrealized gain on marketable securities   6        
Unrealized foreign currency translation adjustments $ (7 ) $ (2 )  
Total comprehensive loss $ (6,486 ) $ (4,475 )  

Condensed Consolidated Statements of Cash Flows
 (in thousands)
    Three months ended
March 31,
Operating Activities:            
Net loss $ (6,485 ) $ (4,473 )  
Adjustments to reconcile net loss to cash flows used in operating activities:              
Depreciation and amortization   86     105    
Stock-based compensation expense, net   181     241    
Change in fair value of warrant liability   755        
Changes in operating assets and liabilities:              
Accounts receivable   105     (201 )  
Inventory, net   (81 )   (451 )  
Other current assets   (81 )   (22 )  
Other assets and liabilities   (16 )   (80 )  
Accounts payable and accrued expenses   (570 )   54    
Net cash used in operating activities   (6,106 )   (4,827 )  
Investing Activities:              
Additions to intangible assets   (85 )      
Purchases of property and equipment   (13 )   (70 )  
Net cash used in investing activities   (98 )   (70 )  
Financing Activities:              
Issuance costs related to 2022 common stock offering   (11 )      
Payments on finance lease liability       (6 )  
Net cash used in financing activities   (11 )   (6 )  
Effect of exchange rate changes on cash   (7 )   (2 )  
Net decrease in cash and cash equivalents   (6,222 )   (4,905 )  
Cash and cash equivalents - beginning of period   17,737     24,205    
Cash and cash equivalents - end of period $ 11,515   $ 19,300    

Primary Logo

Source: Nuwellis, Inc.